You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Total
|
Germline MMR gene mutation
|
IHC MMR protein
|
MSI
|
|---|
|
Absence
|
Presence
|
p value
|
Intact
|
Deficient
|
p value
|
Negative
|
Positive
|
p value
|
|---|
|
Total (cases)
|
111
|
105
|
6
| |
74
|
28
| |
71
|
12
| |
|
Age (years; median [range])
| |
56.00 (31–82)
|
54.00 (48–57)
|
0.440
|
56.50 (32–82)
|
53.50 (31–73)
|
0.102
|
57.00 (32–82)
|
55.00 (40–73)
|
0.658
|
|
Gravidity [median (range)]
| |
2 (0–7)
|
2 (0–5)
|
0.374
|
2 (0–5)
|
2 (0–7)
|
0.437
|
2 (0–7)
|
2 (0–5)
|
0.020
|
|
Parity (median, range)
| |
1 (0–4)
|
1 (0–2)
|
0.779
|
1 (0–4)
|
1 (0–2)
|
0.498
|
1 (0–4)
|
1 (0–3)
|
0.189
|
|
BMI (kg/m2; median [range])
| |
24.98 (19–32)
|
21.60 (19–23)
|
0.010
|
25.66 (19–32)
|
24.27 (20–32)
|
0.622
|
24.98 (19–32)
|
23.87 (19–31)
|
0.343
|
|
Involvement of the lower uterine segment [cases (%)]
|
27
|
24 (22.9)
|
3 (50.0)
|
0.132
|
17 (23.0)
|
9 (32.1)
|
0.343
|
14 (19.7)
|
4 (33.3)
|
0.290
|
|
Type of EC [cases (%)]
| | | |
0.189
| | |
0.983
| | |
0.937
|
|
Type I
|
87
|
81 (77.1)
|
6 (100.0)
| |
58 (78.4)
|
22 (78.6)
| |
54 (76.1)
|
9 (75.0)
| |
|
Type IIa
|
24
|
24 (22.9)
|
0 (0)
| |
16 (21.6)
|
6 (21.4)
| |
17 (23.9)
|
3 (25.0)
| |
|
FIGO stage [cases (%)]b
| | | |
0.012
| | |
0.266
| | |
0.354
|
|
FIGO I
|
87
|
85 (81.0)
|
2 (33.3)
| |
61 (82.4)
|
19 (67.9)
| |
60 (84.5)
|
9 (75.0)
| |
|
FIGO III
|
19
|
15 (14.3)
|
4 (66.7)
| |
11 (14.9)
|
8 (28.6)
| |
8 (11.3)
|
3 (25.0)
| |
|
FIGO IV
|
4
|
4 (3.8)
|
0 (0)
| |
2 (2.7)
|
1 (3.6)
| |
3 (4.2)
|
0 (0)
| |
|
Unknown
|
1
|
1 (1.0)
|
0 (0)
| |
0 (0)
|
0 (0)
| |
0 (0)
|
0 (0)
| |
- Italic values indicate significance of p value (p < 0.05)
- MMR: mismatch repair; IHC: immunohistochemistry; MSI: microsatellite instability; SD: standard deviation; BMI: body mass index; EC: endometrial carcinoma; FIGO: International Federation of Gynecology and Obstetrics
- aAmong 24 cases of type II endometrial cancer, there were nine cases of the serous subtype, three of clear cell carcinoma, four of carcinosarcoma, one of undifferentiated carcinoma, and seven cases of mixed carcinoma (four cases of endometrioid and clear cell carcinomas, two cases of the endometrioid and serous subtypes, and one case of endometrioid subtype and carcinosarcoma)
- bNo patients had FIGO II disease
